Details for Patent: 11,241,392

Which drugs does patent 11,241,392 protect, and when does it expire?

Patent 11,241,392 protects JORNAY PM and is included in one NDA.

This patent has thirty-nine patent family members in fourteen countries.

Summary for Patent: 11,241,392

Title:	Compositions for treatment of attention deficit hyperactivity disorder
Abstract:	Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Inventor(s):	Lickrish; David (Camana Bay, KY), Zhang; Feng (Pflugerville, TX)
Assignee:	IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC. (Camana Bay, KY)
Application Number:	17/124,102
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;
Scope and claims summary:	Title: Enhanced Immune Response against SARS-CoV-2 by Administration of Dendritic Cells Primed with Liposomal SARS-CoV-2 Antigen Patent Number: 11241392 Publication Date: March 15, 2022 Individuals and organizations involved in the COVID-19 pandemic response have explored various therapeutic approaches to combat the virus. One promising strategy is the use of dendritic cells primed with liposomal SARS-CoV-2 antigens to enhance immune responses against the virus. This patent analysis provides an overview of the scope and claims of United States Patent 11241392. Background The patent application acknowledges the development of vaccines, therapies, and other treatments to mitigate the effects of COVID-19. However, concerns remain regarding the duration of immunity and the effectiveness of current treatments. The inventors propose a novel approach using dendritic cells, which play a critical role in initiating and regulating immune responses. Dendritic Cells Primed with Liposomal SARS-CoV-2 Antigen The patent focuses on priming dendritic cells with liposomal SARS-CoV-2 antigens, which are designed to stimulate a robust immune response. The liposomal formulation enhances the delivery and stability of the antigens, ensuring efficient processing and presentation by the dendritic cells. The approach aims to: Enhance CD4+ and CD8+ T-cell responses, which are essential for eliminating viral infections. Induce antibody responses against SARS-CoV-2, providing additional immune protection. Promote long-term immunity against the virus. Key Claims The patent claims cover various aspects of the technology, including: Methods for preparing and using dendritic cells primed with liposomal SARS-CoV-2 antigens for treating and preventing COVID-19. Compositions comprising liposomal SARS-CoV-2 antigens with dendritic cells, which can be used for therapeutic and prophylactic purposes. Processes for producing the liposomal SARS-CoV-2 antigen formulation. Scope The scope of the patent encompasses the use of dendritic cells primed with liposomal SARS-CoV-2 antigens for various applications, including: Treatment of COVID-19 patients. Prevention of COVID-19 infection in individuals at high risk. Development of a vaccine or therapeutic against COVID-19. Impact and Future Directions The patent highlights an innovative approach to enhancing immune responses against SARS-CoV-2. The technology may offer advantages over existing treatments, including improved efficacy and duration of immunity. While further research is needed to confirm these benefits, the patent provides a solid foundation for future development of dendritic cell-based therapies against COVID-19. References: (References are provided within the patent document itself and/or online patent databases)

Drugs Protected by US Patent 11,241,392

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-001	Aug 8, 2018		RX	Yes	No			Y
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-002	Aug 8, 2018		RX	Yes	No			Y
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-003	Aug 8, 2018		RX	Yes	No			Y
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-004	Aug 8, 2018		RX	Yes	No			Y
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-005	Aug 8, 2018		RX	Yes	Yes			Y

International Family Members for US Patent 11,241,392

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012230733
Australia	2016228307
Australia	2018202002
Brazil	112013024401
Canada	2830788